• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

相似文献

1
Estimating The Impact Of Out-Of-Pocket Cost Changes On Abandonment Of HIV Pre-Exposure Prophylaxis.估算自付费用变化对 HIV 暴露前预防药物(PrEP)中断的影响。
Health Aff (Millwood). 2024 Jan;43(1):36-45. doi: 10.1377/hlthaff.2023.00808.
2
Geographic variations of pre-exposure prophylaxis reversal and abandonment among United States counties.美国各县之间的暴露前预防逆转和放弃的地理差异。
AIDS. 2024 Mar 15;38(4):557-566. doi: 10.1097/QAD.0000000000003790. Epub 2023 Nov 15.
3
Cost of implementing HIV pre-exposure prophylaxis at community-based clinics in Indonesia.在印度尼西亚的社区诊所实施艾滋病毒暴露前预防的成本。
Trop Med Int Health. 2024 Jan;29(1):13-22. doi: 10.1111/tmi.13946. Epub 2023 Nov 5.
4
Methods for county-level estimation of pre-exposure prophylaxis coverage and application to the U.S. Ending the HIV Epidemic jurisdictions.县级预防前预防性覆盖估计方法及其在美国终结艾滋病毒流行司法管辖区的应用。
Ann Epidemiol. 2020 Apr;44:16-30. doi: 10.1016/j.annepidem.2020.01.004. Epub 2020 Jan 13.
5
HIV PrEP access and affordability: a multidisciplinary specialty pharmacy model.HIV 预防药物的获取和可负担性:一种多学科专业药房模式。
J Am Pharm Assoc (2003). 2022 May-Jun;62(3):853-858. doi: 10.1016/j.japh.2021.11.024. Epub 2021 Nov 25.
6
Medicare Part D and Cost-Sharing for Antiretroviral Therapy and Preexposure Prophylaxis.医疗保险部分 D 和抗逆转录病毒治疗和暴露前预防的费用分担。
JAMA Netw Open. 2020 Apr 1;3(4):e202739. doi: 10.1001/jamanetworkopen.2020.2739.
7
Out-of-pocket costs and HIV pre-exposure prophylaxis persistence in a US multicity demonstration project.美国多城市示范项目中的自付费用与 HIV 暴露前预防的持续使用。
Health Serv Res. 2020 Aug;55(4):524-530. doi: 10.1111/1475-6773.13285. Epub 2020 Mar 20.
8
Effectiveness and cost effectiveness of oral pre-exposure prophylaxis in a portfolio of prevention programs for injection drug users in mixed HIV epidemics.在混合性艾滋病毒流行情况下针对注射吸毒者的一系列预防项目中,口服暴露前预防的有效性和成本效益。
PLoS One. 2014 Jan 28;9(1):e86584. doi: 10.1371/journal.pone.0086584. eCollection 2014.
9
Pre-exposure prophylaxis for preventing acquisition of HIV: A cross-sectional study of patients, prescribers, uptake, and spending in the United States, 2015-2016.暴露前预防以预防 HIV 感染:2015-2016 年美国患者、处方者、接受情况和支出的横断面研究。
PLoS Med. 2020 Apr 10;17(4):e1003072. doi: 10.1371/journal.pmed.1003072. eCollection 2020 Apr.
10
Cost-effectiveness analysis of HIV pre-exposure prophylaxis in Japan.日本艾滋病病毒暴露前预防的成本效益分析。
J Med Econ. 2023 Jan-Dec;26(1):886-893. doi: 10.1080/13696998.2023.2233824.

引用本文的文献

1
Anticipated Out-Of-Pocket Costs and Prostate Cancer Management Among Men With Commercial Insurance.商业保险男性的预期自付费用与前列腺癌管理
Cancer Med. 2025 Sep;14(17):e71184. doi: 10.1002/cam4.71184.
2
Free antiretrovirals as a key tool against the HIV pandemic: A systematic review.免费抗逆转录病毒药物作为抗击艾滋病大流行的关键工具:一项系统评价。
HIV Med. 2025 Sep;26(9):1329-1342. doi: 10.1111/hiv.70051. Epub 2025 May 28.
3
Why is roll-out of long-acting PrEP agents so slow?长效暴露前预防药物的推广为何如此缓慢?
Curr Opin HIV AIDS. 2025 Jan 1;20(1):48-53. doi: 10.1097/COH.0000000000000899. Epub 2024 Nov 14.
4
Could the Inflation Reduction Act Maximum Fair Price Hurt Patients?《降低通胀法案》的最高公平价格会伤害患者吗?
J Health Econ Outcomes Res. 2024 Nov 27;11(2):154-160. doi: 10.36469/001c.125251. eCollection 2024.
5
Race and ethnicity, not just insurance, is associated with biologics initiation in asthma and related conditions.种族和族裔,而非仅仅保险因素,与哮喘及相关病症中生物制剂的起始使用有关。
J Allergy Clin Immunol. 2025 Mar;155(3):1036-1044. doi: 10.1016/j.jaci.2024.08.001. Epub 2024 Aug 6.

本文引用的文献

1
Cost-Free Preventive Care Under the ACA Faces Legal Challenge.《平价医疗法案》下的免费预防性医疗面临法律挑战。
JAMA. 2023 May 23;329(20):1733-1734. doi: 10.1001/jama.2023.6584.
2
Optimizing Uptake of Long-Acting Injectable Pre-exposure Prophylaxis for HIV Prevention for Men Who Have Sex with Men.优化男男性行为人群长效注射型 HIV 预防用药的使用率。
AIDS Behav. 2023 Aug;27(8):2606-2616. doi: 10.1007/s10461-023-03986-5. Epub 2023 Jan 21.
3
Paying for PrEP: A qualitative study of cost factors that impact pre-exposure prophylaxis uptake in the US.支付 PrEP 药物费用:影响美国人群使用暴露前预防措施的费用因素定性研究。
Int J STD AIDS. 2022 Dec;33(14):1199-1205. doi: 10.1177/09564624221132406. Epub 2022 Oct 21.
4
Opportunities and Challenges of Generic Pre-Exposure Prophylaxis Drugs for HIV.HIV 通用型暴露前预防药物的机遇与挑战。
J Law Med Ethics. 2022;50(S1):32-39. doi: 10.1017/jme.2022.33.
5
The Downstream Impacts of High Drug Costs for PrEP Have Hindered the Promise of HIV Prevention.高药物成本对 PrEP 的下游影响阻碍了 HIV 预防的前景。
J Law Med Ethics. 2022;50(S1):47-50. doi: 10.1017/jme.2022.35.
6
Abandonment of Human Immunodeficiency Virus Preexposure Prophylaxis Prescriptions at Retail Pharmacies-United States, 2019.2019 年美国零售药店终止开具人免疫缺陷病毒暴露前预防处方。
Clin Infect Dis. 2022 Aug 31;75(3):512-514. doi: 10.1093/cid/ciac009.
7
Novel population-level proxy measures for suboptimal HIV preexposure prophylaxis initiation and persistence in the USA.美国次优的HIV暴露前预防启动和持续情况的新型人群水平替代指标。
AIDS. 2021 Nov 15;35(14):2375-2381. doi: 10.1097/QAD.0000000000003030.
8
Evaluation of Algorithms Used for PrEP Surveillance Using a Reference Population From New York City, July 2016-June 2018.利用 2016 年 7 月至 2018 年 6 月来自纽约市的参考人群评估用于 PrEP 监测的算法。
Public Health Rep. 2020 Mar/Apr;135(2):202-210. doi: 10.1177/0033354920904085. Epub 2020 Feb 6.
9
Is Insurance a Barrier to HIV Preexposure Prophylaxis? Clarifying the Issue.保险是否是 HIV 暴露前预防的障碍?澄清问题。
Am J Public Health. 2020 Jan;110(1):61-64. doi: 10.2105/AJPH.2019.305389. Epub 2019 Nov 14.
10
Potential Impact of Interventions to Enhance Retention in Care During Real-World HIV Pre-Exposure Prophylaxis Implementation.现实世界中实施 HIV 暴露前预防时干预措施对提高患者坚持治疗的潜在影响。
AIDS Patient Care STDS. 2019 Oct;33(10):434-439. doi: 10.1089/apc.2019.0064.

估算自付费用变化对 HIV 暴露前预防药物(PrEP)中断的影响。

Estimating The Impact Of Out-Of-Pocket Cost Changes On Abandonment Of HIV Pre-Exposure Prophylaxis.

机构信息

Lorraine T. Dean (

Amy Stewart Nunn, Brown University, Providence, Rhode Island.

出版信息

Health Aff (Millwood). 2024 Jan;43(1):36-45. doi: 10.1377/hlthaff.2023.00808.

DOI:10.1377/hlthaff.2023.00808
PMID:38190604
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC10996384/
Abstract

Oral HIV pre-exposure prophylaxis (PrEP) is highly effective for preventing HIV. Several different developments in the US either threaten to increase or promise to decrease PrEP out-of-pocket costs and access in the coming years. In a sample of 58,529 people with a new insurer-approved PrEP prescription, we estimated risk-adjusted percentages of patients who abandoned (did not fill) their initial prescription across six out-of-pocket cost categories. We then simulated the percentage of patients who would abandon PrEP under hypothetical changes to out-of-pocket costs, ranging from $0 to more than $500. PrEP abandonment rates of 5.5 percent at $0 rose to 42.6 percent at more than $500; even a small increase from $0 to $10 doubled the rate of abandonment. Conversely, abandonment rates that were 48.0 percent with out-of-pocket costs of more than $500 dropped to 7.3 percent when those costs were cut to $0. HIV diagnoses were two to three times higher among patients who abandoned PrEP prescriptions than among those who filled them. These results imply that recent legal challenges to the provision of PrEP with no cost sharing could substantially increase PrEP abandonment and HIV rates, upending progress on the HIV/AIDS epidemic.

摘要

口服 HIV 暴露前预防(PrEP)对于预防 HIV 非常有效。美国的一些新进展可能会增加或减少未来几年 PrEP 的自付费用和可及性。在一个有新保险公司批准的 PrEP 处方的 58529 名患者的样本中,我们估计了在六个自付费用类别中,放弃(未填写)初始处方的患者的风险调整百分比。然后,我们模拟了假设自付费用从 0 美元到超过 500 美元的变化下,有多少患者会放弃 PrEP。自付费用为 0 美元时,放弃 PrEP 的比例为 5.5%,增加到超过 500 美元时,放弃 PrEP 的比例为 42.6%;即使自付费用从 0 美元增加到 10 美元,放弃率也会翻倍。相反,自付费用超过 500 美元时,放弃率为 48.0%,降至自付费用为 0 美元时的 7.3%。放弃 PrEP 处方的患者中 HIV 诊断率比填写处方的患者高出两到三倍。这些结果表明,最近对无共付费用提供 PrEP 的法律挑战可能会大幅增加 PrEP 的放弃率和 HIV 发病率,颠覆艾滋病疫情的进展。